Johnson & Johnson (NYSE:JNJ)’s Zytiga pill wins FDA approval for Prostate Cancer
Johnson & Johnson (NYSE:JNJ)’s Zytiga pill won the U.S. Food and Drug Administration approval. The company’s this treatment will be use for late-stage, hard-to-treat cases of prostate cancer before the chemotherapy. It will provide a new treatment option earlier in the course of the disease.
Previously, the FDA approved Zytiga in April 2011 for patients whose prostate cancer had made progress after chemotherapy. Zytiga when combined with steroid is called prednisone. It was stated by the company’s Janseen unit, European regulators provided positive opinion for expanded use of the once-daily treatment.
According the Richard Pazdur, a director in the oncology segment of the FDA’s drug evaluation and research operation, latest approval indicates the benefit of further evaluating a medicine in an earlier disease setting and provides patients and health-care providers a chance of using Zytiga earlier in the course of treatment.
At the close of the trading day, Johnson & Johnson (NYSE:JNJ) shares rose +0.21% to settle at $70.60. Intraday trading was between $70.26 – $70.80. In the past year, the stock has traded within a range of $61.71 – $72.74. The last session’s volume of 9.70 million shares was down from the average daily trading volume of 10.12 million shares.
Pfizer Inc. (NYSE:PFE) shares were down -0.59% to close at $25.41. The stock traded between $25.36 – $25.60 during the last trading session. In the last 12 months the shares have traded between $20.23 and $26.09. The last session’s volume of 26.89 million shares was a bit lower than their average daily trading volume of 32.15 million shares.
Merck & Co., Inc. (NYSE:MRK) shares in the last session were down -0.34% closing at $44.48. The stock traded in a range of $44.42 – $44.83. In the last year the stock has moved within a range of $34.86 – $48.00. The last session’s volume of 9.35 million shares was down from their average daily trading volume of 11.22 million shares.
Another rival company Sanofi SA (ADR) (NYSE:SNY), traded down -0.22% moving to $46.22. Intraday trading recorded the stock price in a range between $46.03 – $46.34. In the previous 52 weeks the price has traded between $33.03 – $46.34. The last session’s volume of 1.66 million shares was up from their average daily trading volume of 1.37 million shares.